- Home
- AU vs EXEL Comparison
AU vs EXEL Comparison
Compare AU & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AU
- EXEL
- Stock Information
- Founded
- AU 1944
- EXEL 1994
- Country
- AU United States
- EXEL United States
- Employees
- AU N/A
- EXEL N/A
- Industry
- AU Precious Metals
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AU Basic Materials
- EXEL Health Care
- Exchange
- AU Nasdaq
- EXEL Nasdaq
- Market Cap
- AU 10.3B
- EXEL 10.0B
- IPO Year
- AU 1972
- EXEL 2000
- Fundamental
- Price
- AU $24.00
- EXEL $34.37
- Analyst Decision
- AU Hold
- EXEL Buy
- Analyst Count
- AU 5
- EXEL 17
- Target Price
- AU $31.75
- EXEL $32.18
- AVG Volume (30 Days)
- AU 4.8M
- EXEL 1.7M
- Earning Date
- AU 11-07-2024
- EXEL 02-04-2025
- Dividend Yield
- AU 0.91%
- EXEL N/A
- EPS Growth
- AU N/A
- EXEL 441.02
- EPS
- AU 1.34
- EXEL 1.55
- Revenue
- AU $5,299,000,000.00
- EXEL $2,081,598,000.00
- Revenue This Year
- AU $31.43
- EXEL $20.59
- Revenue Next Year
- AU $21.09
- EXEL $1.50
- P/E Ratio
- AU $18.30
- EXEL $22.41
- Revenue Growth
- AU 17.78
- EXEL 17.31
- 52 Week Low
- AU $15.80
- EXEL $19.20
- 52 Week High
- AU $32.57
- EXEL $36.97
- Technical
- Relative Strength Index (RSI)
- AU 39.78
- EXEL 51.61
- Support Level
- AU $23.47
- EXEL $34.30
- Resistance Level
- AU $27.22
- EXEL $36.22
- Average True Range (ATR)
- AU 0.60
- EXEL 0.75
- MACD
- AU -0.07
- EXEL -0.29
- Stochastic Oscillator
- AU 12.27
- EXEL 25.09
About AU AngloGold Ashanti PLC
Anglogold Ashanti PLC is one of the gold miners. The company also produces silver and sulphuric acid as by-products. Its operating divisions are Africa, Australia, and the Americas. The firm generates a majority of its revenue from the Africa region which includes its operations of the Kibali, Iduapriem, Obuasi, Siguiri, and Geita mines.
About EXEL Exelixis Inc.
Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.